Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey bud......there's a gap between HOD on the 26th & LOD on the 27th.......a High Wave, Doji, Bearish reversal pattern forming today......
Keep an eye on the gap.........shoot me a PM bud if you have any top plays in the sector......you seem to alway's have a great eye for biotech plays......TIA........$$$
$2.04 - on nice volume... GL
ONTY: a close above MA(10) would be bullish......a close above MA(20)/Middle Bollinger Band & a new uptrend should begin......
ONTY looking good.....just needs to close above these two crucial resistance levels.......$$$
ONTY: almost formed Bullish Three Inside Up, but today's share price didn't close above yesterday's share price, so the pattern is denied........still looking for confirmation tomorrow for the Bullish Harami buy signal......$$$
ONTY Chart.....formed Bullish Harami reversal pattern on Fri.......need a green close to confirm the buy signal.......
if ONTY can close green today w/ higher close than Fri. Bullish Three Inside Up will form......looking for confirmation today......$$$
BULLISH THREE INSIDE UP
Type: Reversal
Relevance: Bullish
Prior Trend: Bearish
Reliability: High
Confirmation: Suggested
No. of Sticks: 3
Definition: http://www.candlesticker.com/Cs61.asp
The Bullish Three Inside Up Pattern is another name for the Confirmed Bullish Harami Pattern. The third day is confirmation of the bullish trend reversal.
Recognition Criteria:
1. Market is characterized by downtrend.
2. We see a Bullish Harami Pattern in the first two days.
3. Then we see a white candlestick on the third day with a higher close than the second day.
Explanation:
The first two days of this pattern is simply the Bullish Harami Pattern, and the third day confirms the reversal suggested by the Bullish Harami Pattern, since it is a white candlestick closing with a new high for the last three days.
Important Factors:
The reliability of this pattern is very high, but still a confirmation in the form of a white candlestick with a higher close or a gap-up is suggested.
ONTY obtained the license for sabutoclax in Sept 2011...
Drug Targets Hard-To-Reach Leukemia Stem Cells Responsible for Relapses
snip...
An emerging class of drugs called tyrosine kinase inhibitors (TKI) -- such as imitinib (Gleevec), gifitinib (Iressa) and sunitinib (Sutent) -- has become a popular anti-cancer treatment. However, current TKIs are not 100 percent effective. In cases of CML, for example, some LSCs tucked protectively within bone marrow elude destruction, develop resistance to therapy, self-renew and eventually cause the leukemia to dramatically return.
Of clinical importance, they noted that sabutoclax, which suppresses all BCL2 anti-apoptotic proteins, renders these marrow-dwelling blast crisis LSCs sensitive -- and more susceptible -- to TKI-based therapeutics at doses that do not harm normal progenitor cells.
"Our findings show that pan-BCL2 inhibition will be critical for the eradication of cancer stem cells in CML and that there is an essential link between cancer stem cell dormancy, pro-survival BCL2 isoform expression and therapeutic resistance," Jamieson said. "By using a novel pan-BCL2 inhibitor, we may be able to prevent therapeutic resistance by sensitizing malignant stem cell clones to TKIs."
The findings may have implications for treating solid tumor cancers, such as colon, prostate, breast, and brain cancers, noted Daniel J. Goff, the study's first author. "With many of these tumor types being shown to harbor cancer stem cells, it raises the question of whether BCL2 family expression as well as isoform-switching may be crucial for the maintenance of cancer stem cells in these diseases as well," he said. "If so, they may also be candidates for treatment with a BCL2 inhibitor like sabutoclax."
http://www.biotechinvestorsnetwork.com/#!feature-1/cqf5
Sure is but that dont stop it from bringing in HUGE volume all the time! people are defiantly watching this one! $ONTY
I just found this with my screener, It looks like a good pincher move, but I need to check out fundamentals before taking a position. I'm wondering how is the sentiment on this stock?
and what kind of price action is expected?
good luck to all,
Andy
Any idea as to what Monday will bring us?? Any rumors or news floating around out there? $ONTY
Thinkin the same!
Holding on this one. I think it will be a runner maybe 4$. $ONTY
I hope this recovers today. I'm in
Something is going on here. There has got to be something going on behind the scenes! $ONTY
Good question...I wonder what tomorrow will bring $ONTY
Why is the PPS going up today then if the 5% shareholder sold all there shares .. It's already way oversold at these levels with RSI of 30..
This Form 13G signifies that Antipodean Domestic Partners (a prior 5% shareholder) has sold out completely and owns zero shares. It is plainly stated in the text of the filing.
It's an Amendment Statment about who has how much Voting rights..
Someone just bought 5% of $ONTY
This is what SC 13GA form filling means. These are reports required to be filed with the SEC by investors taht own or control more than 5% of the shares of a public company. They are required under the Securities Exchange Act of 1934. It is part of the regulation of tender offers and acquisitions. These filings enable the public to know who the largest investors are of a public company. They are frequently listed in the public company's proxy statement filed with the SEC.
What does this mean?? $ONTY
http://ih.advfn.com/p.php?pid=nmona&article=55769680
It's ready to pop ..
Rebound on this will be amazing. Best and last play for 2012. IMO.
Merck fell the most in seven months after the latest setback in an 11-year effort to develop L-BLP25, a drug originated by U.S. partner Oncothyreon Inc. (ONTY), into a marketable product. While Merck is implying that there may be some hope for the vaccine, it’s still too early to say that, and the company would probably have to conduct further trials, Edouard Aubery, an analyst with Equinet AG, said in a phone interview today.
“This could have been a potential blockbuster, but now it’s been taken off the table,” he said. Aubery had estimated peak annual sales at 1 billion euros ($1.32 billion), with only a 25 percent probability that the vaccine would make it to market after Merck signaled that L-BLP25 was a “high-risk project.”
Stock Drops
Merck fell as much as 4.1 percent to 97.50 euros, the steepest intraday drop since May 9, and was trading down 1.8 percent at 3:21 p.m. in Frankfurt. That pared the stock’s gain this year to 29 percent, valuing Merck at 21.7 billion euros. Oncothyreon plunged as much as 62 percent to $1.71 in Nasdaq trading, the biggest intraday decline since June 17, 2003, and was 59 percent lower at 10:22 p.m. in New York. That gave the company a market value of $106.9 million.
Oncothyreon licensed L-BLP25 to Merck in 2001. Success in the trial, known as Start, would have triggered a $90 million payment to the Seattle-based company, plus royalties on sales in the mid-teens in the U.S. and the high single digits in the rest of the world, the drugmaker said in 2011.
L-BLP25 is a therapeutic vaccine designed to stimulate a patient’s immune system to identify and target cancer cells where the MUC1 gene is present. GlaxoSmithKline Plc (GSK) is also developing a therapeutic cancer vaccine targeting the MAGE-A3 gene which is present in a number of cancers and expects data from late-stage trials next year.
Therapeutic Vaccines
Therapeutic cancer vaccines, which are not to be confused with preventative vaccines like flu shots, have been difficult to develop. Dendreon Corp. (DNDN)’s Provenge, a medicine that targets prostate tumors, is the only approved therapeutic cancer vaccine on the market, yet it has struggled to garner sales due to its $93,000 price tag and competition from existing drugs.
Merck’s Start trial enrolled patients with advanced, inoperable lung cancer whose disease was stable following chemoradiotherapy. The U.S. Food and Drug Administration put the program on hold in March 2010 after a patient developed a brain infection. Merck was allowed to resume two lung cancer trials in June 2010 and scrapped a test of the vaccine in breast cancer.
“It is disappointing” that the testing “did not meet its primary endpoint,” Frances Shepherd, a medical professor at the University of Toronto who coordinated the trial, said in the statement. “However, notable treatment effects were observed in certain subgroups of patients and warrant further investigation of L-BLP25.”
Publishing Data
Merck KGaA, which isn’t related to the U.S.-based Merck & Co. (MRK), plans to submit the results to a peer-reviewed journal for publication and present the data at an international scientific meeting. Stefan Oschmann, head of pharmaceuticals, and Annalisa Jenkins, head of global drug development and medical for Merck Serono, the company’s pharmaceutical unit, were unavailable for comment, Gangolf Schrimpf, a spokesman, said.
Merck is reorganizing with job cuts, factory closings and a review of its new-product pipeline in response to setbacks for some key medicines. Results of separate trials earlier this year showed that Merck’s Erbitux treatment for colorectal cancer and head and neck tumors failed to help patients with advanced cases of stomach cancer and colon cancer.
Merck scrapped development of the cladribine pill for multiple sclerosis in 2011. In September this year, the company withdrew an application to market Erbitux for use in a subgroup of patients with non-small cell lung cancer.
To contact the reporter on this story: Allison Connolly in Frankfurt at aconnolly4@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net
GLTA ... Damn
6:31AM Oncothyreon announces that L-BLP25 (Stimuvax) did not meet primary endpoint of improvement in overall survival in pivotal Phase 3 trial in patients with non-small cell lung cancer (ONTY) 4.50 : Co announced that the pivotal Phase 3 clinical trial of L-BLP25 (formerly referred to as Stimuvax) known as START did not meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell lung cancer. The trial was conducted by Merck Serono, a division of Merck KGaA, under a license agreement with Oncothyreon. Despite not meeting the primary endpoint, notable treatment effects were seen for L-BLP25 in certain subgroups. Further analyses are planned in the coming weeks to explore the potential benefit-risk profile of L-BLP25 in certain populations. Merck Serono will discuss these data with external experts and regulatory authorities over the coming months.
BAD news...Stimuvax misses goal in Phase III trial
http://www.reuters.com/article/2012/12/19/merck-stimuvax-idUSWEA861920121219?feedType=RSS&feedName=rbssHealthcareNews&rpc=43
Where is everyone? ONTY is expected to make a big move soon
See my answer in the previous post.
These were conservative types, and it was hard to see how they were in Big Pharma at all.
It was the Becker Partners show, held around the start of the month. On the panel, one member was Hambrecht & Quist, and you can look up the others.
I didn't question if any of them was long DNDN in March 2007 or April 2009, because I already know their answers.
What NYC forum are we talking about here. Need some context and who the people in the panel were.
Thanks.
io_io: I give up. Which NYC forum? Is there any transcript? Who were these five pundits?
io_io:
I heard about that discussion, and the relatively dire handicapping of the outcome of the START trial.
I guess all I can say is that the point of even trying to speculate in small biotechs is that you think, either individually or in a group, you can out-analyze the Wall Street types.
I think that is generally a fool's errand, as they have the smartest people, lots and lots of time and resources, and most importantly, even in a supposedly egalitarian investing world, access.
However, in the case of a lot of small biotechs, there are occasionally idiosyncrasies out there that the "geniuses" either overlook or poo-poo. I think ONTY and the START trial are a perfect case-in-point.
The odds are always against the small biotech, and survivorship biases abound in clinical trials. But sometimes there is enough data available, if you hunt hard enough and pay really close attention, to be able to transcend platitudes and analyze a situation in the context of its own unique facts.
START has gone on way too long. And the statistical basis for the trial is not the norm -- we know that now. As a result, the platitudes are neutered.
This is what the fabled once in a lifetime opportunity is all about. It's not enough to identify a diamond in the rough. It's also necessary for the "smart money" to see it as a piece of glass.
Arrrggghhh!
TGW
TGW
At a recent NYC forum, the panel were 4-0 against success. So, a second cancer immuno-therapy or bust? You have the floor.
At least one of us can admit to being wrong.........Also, how's Oncothyreon doing? IMO going nowhere fast. Their PI3K seems like a dud....Stimuvax will be on the dud list soon enough.
Ha! You are not the worst. The BV mod + sidekicks have always liked to show up on other boards when a biotech is down. And ignore - or delete - it when its up. I hope MNTA was not too expensive... when I posted there late last year, I had 3 stocks that were all around $9-$10 - AMRN, ELN + SPPI. All 3 have since galloped past MNTA, as I had expected - and the irony is that all 3 were reviled on BV.
ONTY - I wouldnt draw any conclusions from interim data - even the PI3K data was just interim p1 stuff. As for Stimi, I see the interim as a 'pass' and find it optimitic. We will see.
At least one of us can admit to being wrong. Actually I was correct in my earlier prediction on Onyx that was published, but the briefing docs later had me thrown. Even the AdComm admonished Pazdur/FDA for the flip flop between the docs and their comments at the panel. Anyways, Stick to your gut.
Also, how's Oncothyreon doing? IMO going nowhere fast. Their PI3K seems like a dud....Stimuvax will be on the dud list soon enough.
Believe what you will, the truth is a tough medicine to swallow.
Well, between MNTA's ;atest disaster, and your own writing here, I guess the taste of the medicine is quite bitter:
http://www.chimeraresearchgroup.com/2012/06/celgene-onyx-lessons-hubris/
go! ONTY !!!...just hit $4.57 :)
Oncothyreon Reports First Quarter 2012 Financial Results
http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=671018
Nice work as always MACD! Thanx. Maybe the mod should sticky your post.
<<< $ONTY Links! >>> ~ MAC's Quick DD Links without the charts.
Open these links (or the ones you desire) in background tabs
http://help.opera.com/Linux/9.52/en/keyboard.html
http://lifehacker.com/263940/force-links-to-open-in-the-background
PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/ONTY
OTC Markets Company Info ~ http://www.otcmarkets.com/stock/ONTY/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/ONTY/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/ONTY/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/ONTY/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/ONTY/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/ONTY/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/ONTY/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/ONTY/research
Google Finance Summary ~ http://www.google.com/finance?q=ONTY
Google Finance News ~ http://www.google.com/finance/company_news?q=ONTY
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=ONTY
Google Finance Financials ~ http://www.google.com/finance?q=ONTY&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=ONTY
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=ONTY&histperiod=weekly#
Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=ONTY+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=ONTY+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=ONTY+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=ONTY
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=ONTY+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=ONTY+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/ONTY
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/ONTY
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=ONTY+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=ONTY+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=ONTY+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=ONTY+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=ONTY+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=ONTY+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=ONTY+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=ONTY+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=ONTY+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=ONTY+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=ONTY+Cash+Flow&annual
FINVIZ ~ http://finviz.com/quote.ashx?t=ONTY&ty=c&ta=0&p=d
Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=ONTY
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=ONTY
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=ONTY
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=ONTY
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=ONTY
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=ONTY&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260
CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=ONTY&exchange=US
Barchart Quote ~ http://barchart.com/quotes/stocks/ONTY?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/ONTY
Barchart Options Quotes ~ http://barchart.com/options/stocks/ONTY
Barchart Technical Chart ~ http://barchart.com/charts/stocks/ONTY&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/ONTY&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/ONTY
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=ONTY
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/ONTY
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/ONTY
Barchart News Headlines ~ http://barchart.com/news/stocks/ONTY
Barchart Profile ~ http://barchart.com/profile//ONTY
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=ONTY&view=key_statistics
OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=ONTY&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=ONTY&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=ONTY&MarketTicker=NYSE&Typ=S
Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/ONTY/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/ONTY/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/ONTY/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/ONTY/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/ONTY
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/ONTY/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/ONTY/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/ONTY/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/ONTY/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/ONTY/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/ONTY/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=ONTY&sid=1795093&framed=False
The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=ONTY
Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=ONTY
StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=ONTY&num1=567&cobrand=&mode=stock
StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=ONTY
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=ONTY
AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=ONTY&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8
Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=ONTY.PK&WTmodLOC=C4-Officers-5
StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=ONTY®ion=U
Search NASDAQ ~ http://www.nasdaq.com/symbol/ONTY
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/ONTY/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/ONTY/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/ONTY/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=ONTY&selected=ONTY
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=ONTY&selected=ONTY
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/ONTY/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/ONTY/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/ONTY/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/ONTY/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/ONTY/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/ONTY/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/ONTY/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/ONTY/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/ONTY/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/ONTY/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/ONTY/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/ONTY/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/ONTY/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/ONTY/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=ONTY&selected=ONTY
NASDAQ Financials ~ http://www.nasdaq.com/symbol/ONTY/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/ONTY/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/ONTY/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/ONTY/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/ONTY/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/ONTY/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/ONTY/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/ONTY/insider-trades/sells
The Motley Fool ~ http://caps.fool.com/Ticker/ONTY.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/ONTY/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/ONTY/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/ONTY/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/ONTY/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/ONTY/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/ONTY/Statements.aspx?source=icasittab0000009
MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=ONTY
YCharts ~ http://ycharts.com/companies/ONTY
YCharts Performance ~ http://ycharts.com/companies/ONTY/performance
YCharts Dashboard ~ http://ycharts.com/companies/ONTY/dashboard
InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=ONTY&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=ONTY&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=ONTY&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=ONTY
Zacks Quote ~ http://www.zacks.com/stock/quote/ONTY
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=ONTY
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=ONTY
Knobias ~ http://knobias.10kwizard.com/files.php?sym=ONTY
StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=ONTY
Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/ONTY/HOT_TOPIC.html
Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=ONTY&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=ONTY®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=ONTY®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=ONTY®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=ONTY®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=ONTY®ion=USA&culture=en-us
CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=ONTY
TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=ONTY
OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=ONTY&searcharea=e&image1.x=0&image1.y=0
Insidercow ~ http://www.insidercow.com/history/company.jsp?company=ONTY&B1=Search%21
Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=ONTY
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=ONTY&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null
YouTube Symbol Search ~ http://www.youtube.com/results?search_query=ONTY
Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=ONTY
Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=ONTY
Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=ONTY
Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=ONTY
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=ONTY
Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=ONTY
Investorpoint ~ http://www.investorpoint.com/ enter "ONTY" and click search.
Hotstocked ~ http://www.hotstocked.com/ enter "ONTY" and click search.
Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=ONTY
Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=ONTY
DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=ONTY
SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=ONTY
OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=ONTY
Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "ONTY" and click search.
http://www.coordinatedlegal.com/SecretaryOfState.html
http://regsho.finra.org/regsho-Index.html
http://www.shortsqueeze.com/?symbol=ONTY&submit=Short+Quote%99
DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=ONTY
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=ONTY
Check those searches for recent ONTY mentions. If ONTY is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS
MACDlinks
Followers
|
61
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
792
|
Created
|
05/16/06
|
Type
|
Free
|
Moderators |
company web-site - http://www.oncothyreon.com
recent event / CC - http://ir.oncothyreon.com/events.cfm -
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Our pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. Oncothyreon is headquartered in Bellevue, Washington. The Company is traded on the NASDAQ National Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY. We are The Cancer Vaccine People(TM).
Stimuvax
ONTY's drug Stimuvax, in partnership with Merck KGaa, is now in large Phase 3 Pivotal Trial program for NSCLC:
Phase III NSCLC (Lung) "START" Trial - http://www.clinicaltrials.gov/ct2/show/NCT00409188
Phase III NSCLC "INSPIRE" Trial (Asia) - http://www.clinicaltrials.gov/ct2/show/NCT01015443
Phase II NSCLC w/Avastin Trial - http://www.clinicaltrials.gov/ct2/show/NCT00828009
Phase I/II NSCLC Trial in Japan - http://www.clinicaltrials.gov/ct2/show/NCT00960115
Phase IV Long-Term Safety Trial - http://www.clinicaltrials.gov/ct2/show/NCT01423760
Phase II HDPC Trial - http://bethesdatrials.cancer.gov/clinical-research/search_detail.aspx?ProtocolID=NCI-11-C-0247
Pipe-Line - http://www.oncothyreon.com/pipeline/overview.html
Remaining Pipe-Line -
ONT-10 - http://www.oncothyreon.com/pipeline/vaccines/ONT-10/overview.html
PX-866 - http://www.oncothyreon.com/pipeline/small/PX-866/overview.html
Start of Trial with Taxotere - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=526661
Start of Trial with Erbitux - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953
PRESS RELEASES
Oncothyreon Initiates Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Glioblastoma - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561867
Oncothyreon Presents Preclinical Data for ONT-10 and PX-866 at American Association for Cancer Research - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561521
Oncothyreon Announces Publication of Safety & Survival Data From Stimuvax Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788
Oncothyreon Initiates Phase 1/2 Trial of its PI-3 Kinase Inhibitor PX-866 in Combination with Cetuximab - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953
Oncothyreon announces that Merck Serono is resuming the Stimuvax clinical program in lung cancer - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=480296
Oncothyreon announces temporary suspension of Stimuvax clinical trials - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=453976
Oncothyreon announces STRIDE Phase 3 BC trial - June 22, 2009 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38926533
Oncothyreon announces clinical data at ASCO - May 30, 2009 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38259984
Oncothyreon announces development plans - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355043
Merck KGaA buys manufacturing rights for Stimuvax - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355037
ONTY/Merck KGaA amend agreements - Aug 8, 2007http://www.marketwatch.com/news/story/biomira-merck-kgaa-sign-amended/story.aspx?guid=%7B43FD62A1%2D....
MEDICAL PRESENTATIONS
ASCO 2007 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32165
"16 pts were evaluated for this interim safety analysis ..........As of September 2006, 10 pts were still on study treatment."
ASCO 2008 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34755
"The 2-year survival rate of 64% ....compares favorably with previously reported survival for chemoradiation in stage III NSCLC."
ASCO 2009 Stimuvax Abstract - http://www.abstract.asco.org/AbstView_65_31704.html
"a remarkable # of pts received prolonged treatment...16 pts received L-BLP25 for 2.0-7.7 years, 10 pts were treated for >5 years."
COMPLETE MEDICAL PAPERS
Paper summarizing all Stimuvax trials to date - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39761211
Publication of Data From Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788
A Peptide Vaccine Strategy in NSCLC - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39627241
Phase IIb Trial in NSCLC Stage IIIB and IV - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39099793
"The greatest difference in survival was observed in stage IIIB LR patients (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069)"
- Fig 3. Overall survival by study arm - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F3
- Fig 4. Survival analysis for stage IIIB with MFE or stage IV patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F4
- Fig 5. Survival analysis for stage IIIB locoregional patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F5
Detailed Description of START Trial - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39062424
First Interim Look - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58060227
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |